Lung Cancer Interception/INTIME Dream Team - Stand Up to Cancer
Help save a life

This holiday season, Mastercard is standing with us in the fight to end cancer as we know it. From now until December 31st, 2018, if you use a Mastercard to donate to Stand Up To Cancer, Mastercard will TRIPLE your gift, up to $300,000!

That’s triple the impact to support groundbreaking cancer research that will help save lives now!

$25 = $75
$50 = $150
$100 = $300
$250 = $750
GIVE FOR LIFE
For every $1 donated through StandUpToCancer.org with a Mastercard, Mastercard will donate $2, up to $300,000. Offer starts 12/14/18 at 12:01am ET and ends 12/31/18 at 11:59pm ET, or at the $300,000 max, whichever comes first.

Dream Teams

Research  >  Research Portfolio  >  Dream Teams  >  Lung Cancer Interception/INTIME Dream Team

SU2C–LUNGevity Foundation–American Lung Association Lung Cancer Interception Dream Team:
Intercept Lung Cancer Through Immune, Imaging, and Molecular Evaluation (InTIME)

Grant Term: March 2018–February 2022

With innovative technologies and unique patient populations, the SU2C–LUNGevity Foundation–American Lung Association (ALA) Lung Cancer Interception Dream Team seeks to understand how early lung cancer develops and is testing methods to block this development using several complementary approaches. The insights gained from this team’s work will enable the medical and research communities to make major strides in the effort to thwart lung cancer before it occurs.

ABOUT THIS TEAM’S RESEARCH

Lung cancer is the leading cause of cancer death in the United States and worldwide. The SU2C–LUNGevity Foundation–ALA Lung Cancer Interception Dream Team proposes several complementary strategies to help prevent patients from developing lung cancer.

The team is working to create an atlas of precancer of the lung that can help identify the types of cancerous lung tissue that will require aggressive treatment. The team is also attempting to identify treatments that can prevent these abnormal lesions from progressing to invasive lung cancer.

In addition, the researchers are developing two sets of diagnostic tools that will be able to detect lung cancer early. The first set involves using nasal swabs and imaging to confirm whether lung abnormalities found in chest images are lung cancer or benign lung characteristics. The second set involves the use of blood tests to identify patients at the earliest stages of lung cancer recurrence.

MEET THE TEAM

The top scientists and researchers on the SU2C–LUNGevity Foundation–ALA Lung Cancer Interception Dream Team come from a variety of backgrounds and disciplines, which leads them to great insights upon collaboration. Learn more about the SU2C–LUNGevity Foundation–ALA Lung Cancer Interception Dream Team.

Team Members

Avrum Spira, MD
Boston Medical Center Cancer Center
Team Leader

Steven Dubinett, MD
University of California, Los Angeles
Co-leader

Julie Brahmner, MD
Johns Hopkins University
Principal Investigator

Sanjiv “Sam” Gambhir, MD, PhD
Stanford University
Principal Investigator

Matthew Meyerson, MD, PhD
Dana-Farber Cancer Institute
Principal Investigator

Charles Swanton, MBBS
Francis Crick Institute
Principal Investigator

Marcia Horn
International Cancer Advisory Network (ICAN)
Advocate

Kim Norris
Lung Cancer Foundation of America
Advocate

Jessica Vick
Boston University
Project Manager

“We plan to develop technology that can, in a very sensitive way, pick up the small amount of DNA that might be present in the blood of someone who’s harboring a lung cancer deep within their lung tissue—a noninvasive way of measuring a person’s risk of having lung cancer.”

Avrum Spira, MD
Boston Medical Center Cancer Center

TEAM PROGRESS UPDATES

Stand Up To Cancer’s research projects are designed to foster collaborative, swift translational research. The hallmarks of these efforts include rigorous application and selection procedures, sufficient funding to allow scientists to focus on the objectives of the grant, and reviews by senior scientists every six months. These reviews help the investigators capitalize on the latest findings, address potential roadblocks, and collaboratively evolve as the science requires. Please click below to see summaries of research results so far for the SU2C–LUNGevity Foundation–ALA Lung Cancer Interception Dream Team.

TEAM PROGRESS UPDATES

PUBLICATIONS

This team started its work in November 2017; links to publications will be posted when they are available.

CLINICAL TRIALS REFERRALS

Cancer clinical trials allow researchers to study innovative and potentially life-saving new treatments. The goal is to find treatments that are better than what’s currently available; in fact, the therapies offered to today’s cancer patients were almost all studied and made possible by people participating in clinical trials. But many cancer clinical trials aren’t completed because not enough people take part.

At StandUpToCancer.org/ClinicalTrials, you’ll find information and answers to common questions about clinical trials. Learn more and talk to your doctor to see if a clinical trial may be the best choice for you.

You can also connect with EmergingMed, a free and confidential clinical trial matching service that provides access to a vast database to help you identify the clinical trials that might be right for you or your loved one.

LEARN MORE